# **Grasping the Fiscal Issues Surrounding U.S. Entitlement and Welfare Programs**
Prior to delving into entitlement and welfare programs, it is essential to grasp the overarching fiscal landscape of the United States government. The national debt is nearing **$36 trillion**, with expenditures significantly outstripping revenue. Government revenues stand at **18% of GDP** while spending reaches **25% of GDP**, resulting in annual deficits that exacerbate an already formidable debt burden.
A significant portion of expenditures is devoted to **servicing the national debt**, which ranks just behind **Social Security**. Furthermore, **76% of federal spending is obligatory**, encompassing programs like **Medicare, Medicaid, and Social Security**, allowing a mere 24% for discretionary spending. Recent legislative measures, such as the **COVID-19 Relief Bill** and the **Inflation Reduction Act**, have transitioned many traditional discretionary expenses into mandatory spending.
Given these fiscal realities, any effective strategy to stabilize the budget needs to consider both **discretionary and mandatory expenditures**.
—
## **The Influence of Inflation and Interest Rates on U.S. Economic Viability**
In the preceding four years, the nation has witnessed **accelerated inflation**, prompting the Federal Reserve to implement **quantitative tightening**, which involves pulling liquidity from the economy to temper inflation. At its essence, inflation is a **monetary issue**, where an increase in the money supply diminishes the worth of each dollar.
By **raising interest rates**, the Federal Reserve aims to dissuade borrowing, which **lessens money supply** but simultaneously slows economic growth, increasing borrowing costs for both consumers and businesses. While enhancing the **productivity** of goods and services would be a preferred method of tackling inflation without adversely impacting the economy, notable structural obstacles complicate this goal.
—
## **Projected Growth of Government Debt: A Long-Term Challenge**
Current forecasts indicate that over the forthcoming **10 years**, the U.S. government will expend **$89 trillion** while securing only **$68 trillion** in revenue. This **$21 trillion deficit** is set to elevate the **national debt to $57 trillion**, an unsustainable figure that heightens the potential for fiscal instability.
To address this debt, the government has two main avenues:
1. **Increased Taxes** – Elevating taxes to generate revenue could alleviate some of the debt burden but may also **hamper economic growth** by diminishing consumer disposable income and investment funds for businesses.
2. **Money Creation & Low Interest Rates (Quantitative Easing)** – The Federal Reserve might persist in acquiring U.S. debt to maintain low interest rates, yet this strategy tends to create **inflationary pressures** over time.
Should interest rates rise sharply, the expense of **servicing this immense debt load** will soar, potentially leading to financial turmoil.
—
## **Financial Prospects for Medicare: An Impending Crisis**
The **Medicare Board of Trustees** has cautioned that **Medicare Part A’s hospital trust fund** is projected to become depleted by **2036**. Simultaneously, general tax revenues supporting **Medicare Parts B and D** are anticipated to surpass **45% of total Medicare expenditures** within the next **seven years**, imposing an increasing strain on taxpayers.
Essential Medicare financial forecasts encompass:
– **Medicare costs are expected to grow from $1 trillion today to $2 trillion by 2033.**
– **Increased premiums for seniors**—with monthly deductions from Social Security likely rising from **$164.90 today to $299.80 by 2033**.
– By **2040, 26.7% of federal income tax revenue** will be necessary to sustain Medicare.
In addition, **Medicare’s reimbursement rates for hospitals and doctors may soon prove untenable**, possibly leading to **reduced access to care** for beneficiaries.
—
## **The Inflation Reduction Act and Its Impact on Medicare & Prescription Drug Prices**
A significant aspect of the **Inflation Reduction Act (IRA)** was the anticipated **$30 billion decrease** in financing for Medicare *Part D* (the prescription drug initiative). However, while costs to the government are expected to diminish, these reductions will adversely affect **insurance companies’ ability to provide prescription drug coverage**, leading to **increased premiums, diminished benefits, and fewer plan choices**.
Further implications of the IRA include:
– Diminishing incentives for the pharmaceutical industry regarding drug research and development.
– **40 biotech projects** and **22 experimental drugs** have already been shelved due to concerns about IRA-mandated price controls.
– The decrease in pharmaceutical innovation is projected to lower **life expectancy**, with researchers estimating up to **331.5 million life years forfeited** by **2039** due to a reduction in newly available medications.
Though the IRA was promoted as a strategy to mitigate inflation, its provisions have negatively influenced **seniors’ drug accessibility and overall medical advancements**, raising concerns about its lasting effects on healthcare.
—